Compare AstraZeneca plc (AZN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Snap On Incorporated — how do they compare? AstraZeneca plc trades at $166.87 (market cap $253.13B), while Snap On Incorporated trades at $404.38 (market cap $20.96B). The key difference: AstraZeneca plc is far larger — about 12.1× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| AZN | SNA | |
|---|---|---|
Market Cap | $253.13B | $20.96B |
Sector | Health | Technology |
52-Week High | $209.48 | $413.62 |
52-Week Low | $137.44 | $313.01 |
Enterprise Value | $279.37B | $20.48B |
Dividend Yield | 1.92% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Snap-on Incorporated (SNA) trades at $401.11, down 0.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong profitability with a 19.6% net income margin and ROE of 17.83%, while recent acquisitions like Diesel Laptops for $100 million aim to expand heavy-duty diagnostics capabilities. Q1 2026 earnings missed expectations slightly, but Q2 results are anticipated.
Outlook remains positive with analyst consensus favoring Buy ratings (64.71%) and a $407.50 price target, though risks include margin pressures and muted growth forecasts. The stock offers stability with consistent dividends and share repurchases, but investors should monitor competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
